** Drug developer Sangamo Therapeutics' shares SGMO.O fall 47.4% to $1.23 in extended trading
** SGMO said that Pfizer PFE.N terminated partnership to develop hemophilia A gene therapy
** Co's collaboration and license agreement with Pfizer will terminate, effective April 21, 2025
** In July, PFE announced positive results from a late-stage study of therapy
** SGMO said it plans to explore all options to commercialize the hemophilia A gene therapy, including seeking a new partner
** Up to Monday's close, SGMO is up 330.7% YTD
(Reporting by Rishi Kant in Bengaluru)
((Rishi.Kant@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.